These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 14696044

  • 1. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R, Lecht S, Lazarovici P.
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [Abstract] [Full Text] [Related]

  • 2. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA.
    Int Rev Neurobiol; 2011 Feb; 100():127-49. PubMed ID: 21971006
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [Abstract] [Full Text] [Related]

  • 11. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH, Chen JJ.
    Clin Neuropharmacol; 2007 Oct; 30(3):150-68. PubMed ID: 17545750
    [Abstract] [Full Text] [Related]

  • 12. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O, Amit T, Bar-Am O, Youdim MB.
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [Abstract] [Full Text] [Related]

  • 13. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH, Chen JJ.
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [Abstract] [Full Text] [Related]

  • 14. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M, Sanz E.
    Int Rev Neurobiol; 2011 Dec; 100():217-36. PubMed ID: 21971010
    [Abstract] [Full Text] [Related]

  • 15. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 16. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J.
    Vopr Med Khim; 1997 Oct; 43(6):482-93. PubMed ID: 9503565
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.
    Tatton W, Chalmers-Redman R, Tatton N.
    J Neural Transm (Vienna); 2003 May; 110(5):509-15. PubMed ID: 12721812
    [Abstract] [Full Text] [Related]

  • 18. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Naoi M, Maruyama W, Inaba-Hasegawa K.
    Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
    [Abstract] [Full Text] [Related]

  • 19. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K, Szende B.
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [Abstract] [Full Text] [Related]

  • 20. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL, Page RL, Ruscin JM.
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.